País: Singapur
Idioma: anglès
Font: HSA (Health Sciences Authority)
CIPROFLOXACIN HYDROCHLORIDE
BAYER (SOUTH EAST ASIA) PTE LTD
J01MA02
250 mg
TABLET, FILM COATED
CIPROFLOXACIN HYDROCHLORIDE 291.0MG
ORAL
Prescription Only
Bayer AG
ACTIVE
1989-06-07
Ciprobay Tab & IV PI_SG_CCDS16_3July2014 NAME OF THE MEDICINAL PRODUCT Ciprobay 250mg film-coated tablets Ciprobay 500mg film-coated tablets Ciprobay 100 Infusion Solution 100 mg/50 ml Ciprobay 200 Infusion Solution 200 mg/100 ml QUALITATIVE AND QUANTITATIVE COMPOSITION 250MG Each film-coated tablet contains 250 mg ciprofloxacin as hydrochloride. 500MG Each film-coated tablet contains 500 mg ciprofloxacin as hydrochloride. 100 MG/50 ML Each glass bottle with 50 ml solution for infusion contains 100 mg ciprofloxacin. The sodium content is 177 mg (7.7 mmol). 200 MG/100 ML Each glass bottle with 100 ml solution for infusion contains 200 mg ciprofloxacin. The sodium content is 354 mg (15.4 mmol). PHARMACEUTICAL FORM 250MG Round, nearly white to slightly yellowish film-coated tablets marked wi th “CIP score 250” on one side and a “Bayer cross” on the reverse side. The tablet can be divided into equal halves. 500MG Oblong, nearly white to slightly yellowish film- coated tablets marked with “CIP score 500” on one side and “BAYER” on the reverse side. The tablet can be divided into equal halves. 100 MG/50 ML Clear, nearly colourless to slightly yellowish solution. The pH-value of the solution for infusion ranges from 3.9 to 4.5. 200 MG/100 ML Clear, nearly colourless to slightly yellowish solution. The pH-value of the solution for infusion ranges from 3.9 to 4.5. INDICATIONS Uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens. Infections of the respiratory tract: Ciprofloxacin can be regarded as an advisable treatment for pneumonias caused by _Klebsiella _ spp., _Enterobacter_ spp.,_ Proteus_ spp., _E. coli_,_ Pseudomonas, Haemophilus_ spp._, Moraxella _ _Catarrhalis, Legionel Llegiu el document complet
Ciprobay Tab & IV PI_SG_CCDS20_February 2022 NAME OF THE MEDICINAL PRODUCT Ciprobay 250mg film-coated tablets Ciprobay 500mg film-coated tablets Ciprobay 100 Infusion Solution 100 mg/50 ml Ciprobay 200 Infusion Solution 200 mg/100 ml QUALITATIVE AND QUANTITATIVE COMPOSITION 250MG Each film-coated tablet contains 250 mg ciprofloxacin as hydrochloride. 500MG Each film-coated tablet contains 500 mg ciprofloxacin as hydrochloride. 100 MG/50 ML Each glass bottle with 50 ml solution for infusion contains 100 mg ciprofloxacin. The sodium content is 177 mg (7.7 mmol). 200 MG/100 ML Each glass bottle with 100 ml solution for infusion contains 200 mg ciprofloxacin. The sodium content is 354 mg (15.4 mmol). PHARMACEUTICAL FORM 250MG Round, nearly white to slightly yellowish film-coated tablets marked with “CIP score 250” on one side and a “Bayer cross” on the reverse side. The tablet can be divided into equal halves. 500MG Oblong, nearly white to slightly yellowish film-coated tablets marked with “CIP score 500” on one side and “BAYER” on the reverse side. The tablet can be divided into equal halves. 100 MG/50 ML Clear, nearly colourless to slightly yellowish solution. The pH-value of the solution for infusion ranges from 3.9 to 4.5. 200 MG/100 ML Clear, nearly colourless to slightly yellowish solution. The pH-value of the solution for infusion ranges from 3.9 to 4.5. INDICATIONS Uncomplicated and complicated infections caused by ciprofloxacin sensitive pathogens. Infections of the respiratory tract: Ciprofloxacin can be regarded as an advisable treatment for pneumonias caused by _Klebsiella _ spp., _Enterobacter_ spp.,_ Proteus_ spp., _E. coli_,_ Pseudomonas, Haemophilus_ spp._, Moraxella _ _Catarrhalis, Legionella_ spp._ and Staphylococcus_. Infections of the middle ear (otitis media), of the paranasal sinuses (sinusitis), especially if these are caused by Gram-negative organisms including _Pseudomonas_ or by _Staphylococcus. _ Ciprobay Tab & IV PI_SG_CCDS20_February 2022 2 Infections of the eyes Infection Llegiu el document complet